Catalyst

Slingshot members are tracking this event:

Tesaro (TSRO) planning for NDA and MAA submissions for Niraparib in the second half of this year

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
TSRO

100%

Additional Information

Additional Relevant Details TESARO has initiated a rolling submission of a New Drug Application (NDA) for niraparib to the FDA, and intends to complete this submission during the fourth quarter. The Marketing Authorization Application (MAA) for niraparib is planned for submission to the European Medicines Agency (EMA) in the fourth quarter.
http://ir.tesarobio....
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 12, 2016
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Nda Filing, Maa Submission, Niraparib, Parp Inhibitors